Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy
Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Dipen J. Parekh(University of Miami), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Vivek Venkatramani(University of Miami), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Alon Z. Weizer(University of Michigan), Sanoj Punnen(University of Miami), Tracey L. Krupski(University of Virginia Cancer Center), Marcus L. Quek(Loyola University Medical Center), Shyamal Raolji(University of Miami), Mark L. Gonzalgo(University of Miami), Isildinha M. Reis(University of Miami), Badrinath R. Konety(Allina Health), Daniel A. Barocas(Vanderbilt University Medical Center), Michael Woods(University of Cambridge), Nachiketh Soodana‐Prakash(University of Miami), Atreya Dash(University of Washington), Norm D. Smith(Caris Life Sciences (United States)), Mathew Tollefson(WinnMed), Erik P. Castle(WinnMed)
Cited by 34
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
|Journal of the National Comprehensive Cancer Network|2021|532